Zura Bio Limited (NASDAQ:ZURA) Sees Significant Growth in Short Interest

Zura Bio Limited (NASDAQ:ZURA) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 3,847,872 shares, a growth of 27.7% from the January 15th total of 3,012,119 shares. Based on an average trading volume of 1,149,960 shares, the days-to-cover ratio is currently 3.3 days. Approximately 7.6% of the shares of the company are sold short. Approximately 7.6% of the shares of the company are sold short. Based on an average trading volume of 1,149,960 shares, the days-to-cover ratio is currently 3.3 days.

Institutional Investors Weigh In On Zura Bio

A number of large investors have recently bought and sold shares of the business. Allworth Financial LP bought a new position in Zura Bio in the 4th quarter valued at $30,000. Savant Capital LLC grew its holdings in shares of Zura Bio by 190.4% during the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after purchasing an additional 21,249 shares during the last quarter. Scientech Research LLC acquired a new stake in shares of Zura Bio in the third quarter valued at $45,000. AQR Capital Management LLC bought a new position in shares of Zura Bio in the first quarter valued at about $72,000. Finally, Forefront Wealth Partners LLC bought a new position in shares of Zura Bio in the third quarter valued at about $93,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Stock Performance

ZURA opened at $6.08 on Monday. The firm’s 50-day simple moving average is $5.20 and its 200-day simple moving average is $3.73. Zura Bio has a twelve month low of $0.97 and a twelve month high of $6.88. The firm has a market cap of $395.32 million, a price-to-earnings ratio of -9.35 and a beta of 0.21.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). As a group, sell-side analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Wedbush assumed coverage on Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 target price for the company. Chardan Capital restated a “buy” rating and issued a $10.00 price objective on shares of Zura Bio in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Finally, Leerink Partners raised shares of Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.